PAR.AX
Price:
$0.42
Market Cap:
$163.56M
Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.[Read more]
Industry
Biotechnology
IPO Date
2015-08-19
Stock Exchange
ASX
Ticker
PAR.AX
According to Paradigm Biopharmaceuticals Limited’s latest financial reports and current stock price. The company's current ROE is -203.64%. This represents a change of 206.02% compared to the average of -66.54% of the last 4 quarters.
The mean historical ROE of Paradigm Biopharmaceuticals Limited over the last ten years is -62.33%. The current -203.64% ROE has changed 226.68% with respect to the historical average. Over the past ten years (40 quarters), PAR.AX's ROE was at its highest in in the January 2015 quarter at 0%. The ROE was at its lowest in in the June 2015 quarter at -157.60%.
Average
-62.33%
Median
-37.87%
Minimum
-246.38%
Maximum
-10.82%
Discovering the peaks and valleys of Paradigm Biopharmaceuticals Limited ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 285.42%
Maximum Annual ROE = -10.82%
Minimum Annual Increase = -107.10%
Minimum Annual ROE = -246.38%
Year | ROE | Change |
---|---|---|
2024 | -246.38% | 154.77% |
2023 | -96.71% | 4.25% |
2022 | -92.76% | 111.70% |
2021 | -43.82% | 285.42% |
2020 | -11.37% | -39.76% |
2019 | -18.87% | -57.73% |
2018 | -44.65% | 39.83% |
2017 | -31.93% | 22.62% |
2016 | -26.04% | 140.63% |
2015 | -10.82% | -107.10% |
The current ROE of Paradigm Biopharmaceuticals Limited (PAR.AX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-145.28%
5-year avg
-98.21%
10-year avg
-62.33%
Paradigm Biopharmaceuticals Limited’s ROE is less than PolyNovo Limited (7.45%), greater than AVITA Medical, Inc. (-39.79%), less than Opthea Limited (520.65%), greater than Mesoblast Limited (-17.79%), greater than Volpara Health Technologies Limited (-17.60%),
Company | ROE | Market cap |
---|---|---|
7.45% | $1.44B | |
-39.79% | $380.10M | |
520.65% | $923.44M | |
-17.79% | $3.22B | |
-17.60% | $291.26M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Paradigm Biopharmaceuticals Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Paradigm Biopharmaceuticals Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Paradigm Biopharmaceuticals Limited's ROE?
How is the ROE calculated for Paradigm Biopharmaceuticals Limited (PAR.AX)?
What is the highest ROE for Paradigm Biopharmaceuticals Limited (PAR.AX)?
What is the 3-year average ROE for Paradigm Biopharmaceuticals Limited (PAR.AX)?
What is the 5-year average ROE for Paradigm Biopharmaceuticals Limited (PAR.AX)?
How does the current ROE for Paradigm Biopharmaceuticals Limited (PAR.AX) compare to its historical average?